Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma

被引：3

作者：

Calvo E. ^{[1
]}

Maroto P. ^{[2
]}

Del Muro X.G. ^{[3
]}

Climent M.A. ^{[4
]}

González-Larriba J.L. ^{[5
]}

Esteban E. ^{[6
]}

López R. ^{[7
]}

Paz-Ares L. ^{[8
]}

Bellmunt J. ^{[9
]}

Castellano D. ^{[10
]}

机构：

[1] Hospital de Madrid-CIOCC, Madrid

[2] Hospital de la Santa Creu i San Pau, Barcelona

[3] Institut Català d'Oncologia, Barcelona

[4] Instituto Valenciano de Oncología, Valencia

[5] Hospital Clínico San Carlos, Madrid

[6] Hospital Universitario Central de Asturias, Oviedo

[7] Complexo Hospitalario Universitario de Santiago, A Coruña

[8] Hospital Virgen Del Rocío, Sevilla

[9] Hospital Del Mar, Barcelona

[10] Medical Oncology Service, Hospital Universitario 12 de Octubre, 28041 Madrid, Avda. De Córdoba, s/n

来源：

Cancer and Metastasis Reviews | 2010年 / 29卷 / Suppl 1期

关键词：

Cancer treatment; Renal cell carcinoma; Spanish Oncology Genitourinary Group;

D O I：

10.1007/s10555-010-9231-6

中图分类号：

学科分类号：

摘要：

The speed at which targeted therapies are being developed and incorporated into the treatment of advanced renal cell carcinoma (RCC) is surprising. After decades in which the only systemic treatment options available for advanced disease were interleukin-2 and interferon-α, in the last decade, six new targeted therapies have emerged showing meaningful clinical benefits to patients with advanced RCC through phase III trials. Recently, the Spanish Oncology Genitourinary Group issued its first public statement of recommendations for the optimal management of advanced RCC. However, most pivotal phase III trials on which these recommendations were based have been updated and/or fully reported. Moreover, a new multikinase inhibitor, pazopanib, has emerged with good quality clinical data. In this report, we review in depth the latest phase III data of targeted therapies for advanced RCC and update our recommendations. Furthermore, we hypothesize about the best environment for patients with advanced RCC to receive cancer therapy. © 2010 Springer Science+Business Media, LLC.

引用

页码：S1 / S10

页数：9

共 62 条

[1]

Jemal A., Siegel R., Ward E., Et al., Cancer statistics, 2009, CA: A Cancer Journal for Clinicians, 59, pp. 225-249, (2009)

[2]

Bellmunt J., Calvo E., Castellano D., Et al., Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer, Cancer Chemotherapy and Pharmacology, 63, SUPPL. 1, (2009)

[3]

Amato R.J., Chemotherapy for renal cell carcinoma, Seminars in Oncology, 27, pp. 177-186, (2000)

[4]

Lam J.S., Leppert J.T., Figlin R.A., Et al., Surveillance following radical or partial nephrectomy for renal cell carcinoma, Current Urology Reports, 6, pp. 7-18, (2005)

[5]

Bukowski R.M., Prognostic factors for survival in metastatic renal cell carcinoma: Update 2008, Cancer, 115, pp. 2273-2281, (2009)

[6]

Lughezzani G., Capitanio U., Jeldres C., Et al., Prognostic significance of lymph node invasion in patients with metastatic renal cell carcinoma: A population-based perspective, Cancer, 115, pp. 5680-5687, (2009)

[7]

Ljungberg B., Landberg G., Alamdari F.I., Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy, Scandinavian Journal of Urology and Nephrology, 34, 4, pp. 246-251, (2000)

[8]

Atkins M.B., Ernstoff M.S., Figlin R.A., Flaherty K.T., George D.J., Kaelin Jr. W.G., Kwon E.D., Libermann T.A., Linehan W.M., McDermott D.F., Ochoa A.C., Pantuck A.J., Rini B.I., Rosen M.A., Sosman J.A., Sukhatme V.P., Vieweg J.W., Wood C.G., King L., Innovations and challenges in renal cell carcinoma: Summary statement from the Second Cambridge Conference, Clinical Cancer Research, 13, (2007)

[9]

Tunuguntla H.S., Jorda M., Diagnostic and prognostic molecular markers in renal cell carcinoma, Journal d'Urologie, 179, pp. 2096-2102, (2008)

[10]

Escudier B., Eisen T., Stadler W.M., Et al., Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial, Journal of Clinical Oncology, 27, pp. 3312-3318, (2009)

← 1 2 3 4 5 6 7 →